{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:44:46Z","timestamp":1793691886945,"version":"4.5.1"},"reference-count":101,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.euroneuro.2015.12.035","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T09:17:38Z","timestamp":1451380658000},"page":"163-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Pharmacogenetics of clozapine response and induced weight gain: A comprehensive review and meta-analysis"],"prefix":"10.1016","volume":"26","author":[{"given":"Florence","family":"Gressier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Porcelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Calati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Serretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2015.12.035_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/mp.2010.14","article-title":"Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs","volume":"16","author":"Adkins","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(95)92168-0","article-title":"Association between clozapine response and allelic variation in 5-HT2A receptor gene","volume":"346","author":"Arranz","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib501","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0304-3940(96)13094-9","article-title":"Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine","volume":"217","author":"Arranz","year":"1996","journal-title":"Neurosci Lett."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/sj.mp.4000652","article-title":"The serotonin transporter and clozapine response","volume":"5","author":"Arranz","year":"2000","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib4","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/S0140-6736(00)02221-2","article-title":"Pharmacogenetic prediction of clozapine response","volume":"355","author":"Arranz","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.mp.4000348","article-title":"Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine","volume":"3","author":"Arranz","year":"1998","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0920-9964(98)00032-2","article-title":"Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response","volume":"32","author":"Arranz","year":"1998","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2010.11.030","article-title":"Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics","volume":"125","author":"Bai","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajmg.b.30770","article-title":"Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients","volume":"150B","author":"Barlas","year":"2009","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.psyneuen.2015.03.012","article-title":"Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: a meta-analysis","volume":"56","author":"Bartoli","year":"2015","journal-title":"Psychoneuroendocrinology"},{"issue":"Suppl 23","key":"10.1016\/j.euroneuro.2015.12.035_bib10","first-page":"45","article-title":"Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle","volume":"62","author":"Basile","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib11","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1097\/00001756-200006260-00042","article-title":"Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response","volume":"11","author":"Birkett","year":"2000","journal-title":"Neuroreport"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1472-8206.2009.00751.x","article-title":"Pharmacogenetic of response efficacy to antipsychotics in schizophrenia: pharmacodynamic aspects. Review and implications for clinical research","volume":"24","author":"Blanc","year":"2010","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0304-3940(99)01000-9","article-title":"No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response","volume":"280","author":"Bolonna","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000071211","article-title":"Association analysis of the genetic variants of the N-methyl D-aspartate receptor subunit 2b (NR2b) and treatment-refractory schizophrenia in the Chinese","volume":"47","author":"Chiu","year":"2003","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib508","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s002130050799","article-title":"Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs","volume":"141","author":"Cohen","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib15","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/bmj.315.7121.1533","article-title":"Meta-analysis: principles and procedures","volume":"315","author":"Egger","year":"1997","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/(SICI)1096-8628(19960920)67:5<455::AID-AJMG3>3.0.CO;2-J","article-title":"Assessment of association of D3 dopamine receptor MscI polymorphism with schizophrenia: analysis of symptom ratings, family history, age at onset, and movement disorders","volume":"67","author":"Gaitonde","year":"1996","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib17","first-page":"E608","article-title":"Metabolic and cellular plasticity in white adipose tissue I: effects of beta3-adrenergic receptor activation","volume":"289","author":"Granneman","year":"2005","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/JCP.0b013e31819302c3","article-title":"Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine","volume":"29","author":"Gunes","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0920-9964(02)00205-0","article-title":"Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response","volume":"58","author":"Guti\u00e9rrez","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00008571-200302000-00007","article-title":"Human genetic variations in the 5HT2A receptor: a single nucleotide polymorphism identified with altered response to clozapine","volume":"13","author":"Harvey","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00041444-200209000-00009","article-title":"Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment","volume":"12","author":"Hong","year":"2002","journal-title":"Psychiatr. Genet."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00008571-200104000-00010","article-title":"Genetic variants of the serotonin system and weight change during clozapine treatment","volume":"11","author":"Hong","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pnpbp.2011.11.018","article-title":"Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: Replication and exploration","volume":"37","author":"Hwang","year":"2012","journal-title":"Prog. neuro -Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib24","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/tpj.2009.65","article-title":"Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant","volume":"10","author":"Hwang","year":"2010","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib510","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.euroneuro.2005.09.004","article-title":"Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment","volume":"16","author":"Hwang","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00041444-200303000-00001","article-title":"Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis","volume":"13","author":"Jonsson","year":"2003","journal-title":"Psychiatr. Genet."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib26","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4306\/pi.2011.8.3.262","article-title":"Genetic polymorphisms in the HTR2C and peroxisome proliferator-activated receptors are not associated with metabolic syndrome in patients with schizophrenia taking clozapine","volume":"8","author":"Kang","year":"2011","journal-title":"Psychiatry Investig."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib512","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.mp.4000729","article-title":"Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia","volume":"5","author":"Kaiser","year":"2000","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1590\/1516-4446-2012-0970","article-title":"Pharmacogenetics in schizophrenia: a review of clozapine studies","volume":"35","author":"Kohlrausch","year":"2013","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib28","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.2217\/14622416.9.10.1429","article-title":"G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics","volume":"9","author":"Kohlrausch","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib29","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jpsychires.2010.04.003","article-title":"Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics","volume":"44","author":"Kohlrausch","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib507","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0924-977X(96)00380-X","article-title":"Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects","volume":"7","author":"Kohn","year":"1997","journal-title":"Eur Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib30","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1006\/geno.1995.1042","article-title":"Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C)","volume":"27","author":"Lappalainen","year":"1995","journal-title":"Genomics"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib31","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1176\/ajp.149.1.68","article-title":"Clozapine-induced weight gain: prevalence and clinical relevance","volume":"149","author":"Leadbetter","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib32","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/JCP.0b013e31825ac35c","article-title":"Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response","volume":"32","author":"Lee","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.schres.2011.08.007","article-title":"The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response","volume":"132","author":"Lett","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib34","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib35","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/ajp.151.12.1744","article-title":"Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome","volume":"151","author":"Lieberman","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib36","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1192\/bjp.168.5.571","article-title":"Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine","volume":"168","author":"Litman","year":"1996","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib37","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2011.03.038","article-title":"Effect of clozapine on the dimerization of serotonin 5-HT(2A) receptor and its genetic variant 5-HT(2A)H425Y with dopamine D(2) receptor","volume":"659","author":"Lukasiewicz","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib38","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1006\/bbrc.1996.1296","article-title":"Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system","volume":"225","author":"Lundstrom","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib39","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1001\/archgenpsychiatry.2012.191","article-title":"Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain","volume":"69","author":"Malhotra","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib40","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/sj.mp.4000288","article-title":"The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response","volume":"3","author":"Malhotra","year":"1998","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib41","first-page":"92","article-title":"Allelic variation in the promoter region of the dopamine D2 receptor gene and clozapine response","volume":"36","author":"Malhotra","year":"1999","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib42","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1176\/ajp.153.8.1092","article-title":"Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine","volume":"153","author":"Malhotra","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0304-3940(02)00178-7","article-title":"Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response","volume":"333","author":"Mancama","year":"2002","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0893-133X(98)00007-4","article-title":"Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients","volume":"19","author":"Masellis","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0920-9964(00)00016-5","article-title":"Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia","volume":"47","author":"Masellis","year":"2001","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib46","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/S0140-6736(95)91785-3","article-title":"Genetic variation of 5-HT2A receptor and response to clozapine","volume":"346","author":"Masellis","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib47","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/hup.1114","article-title":"Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in clozapine- and olanzapine-treated patients","volume":"25","author":"Melkersson","year":"2010","journal-title":"Hum. Psychopharmacol."},{"issue":"Suppl B","key":"10.1016\/j.euroneuro.2015.12.035_bib48","first-page":"47","article-title":"An overview of the mechanism of action of clozapine","volume":"55","author":"Meltzer","year":"1994","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib49","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","article-title":"Clozapine: balancing safety with superior antipsychotic efficacy","volume":"6","author":"Meltzer","year":"2012","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib50","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajmg.b.30115","article-title":"Clozapine-induced weight gain associated with the 5HT2C receptor -759C\/T polymorphism","volume":"133B","author":"Miller","year":"2005","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0165-1781(97)00036-X","article-title":"Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment","volume":"71","author":"Monteleone","year":"1997","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib52","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.euroneuro.2005.02.001","article-title":"Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia","volume":"15","author":"Muller","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00041444-199621000-00005","article-title":"5-HT2 receptor gene locus: association with schizophrenia or treatment response not detected","volume":"6","author":"Nimgaonkar","year":"1996","journal-title":"Psychiatr. Genet."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib54","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(95)92756-5","article-title":"Genetic variation of the 5-HT2A receptor and response to clozapine","volume":"346","author":"Nothen","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib55","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1046\/j.1471-4159.1997.68052186.x","article-title":"A naturally occurring amino acid substitution of the human serotonin 5-HT2A receptor influences amplitude and timing of intracellular calcium mobilization","volume":"68","author":"Ozaki","year":"1997","journal-title":"J. Neurochem."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib56","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1001\/archpsyc.1995.03950220087016","article-title":"Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors","volume":"52","author":"Pollmacher","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib57","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.euroneuro.2011.10.003","article-title":"Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy","volume":"22","author":"Porcelli","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib509","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/sj.mp.4001191","article-title":"D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine","volume":"8","author":"Potkin","year":"2003","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib58","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00213-012-2773-2","article-title":"Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia","volume":"224","author":"Rajkumar","year":"2012","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib506","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/archpsyc.1994.03950110072009","article-title":"Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine","volume":"51","author":"Rao","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib59","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1176\/appi.ajp.160.4.677","article-title":"Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain","volume":"160","author":"Reynolds","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib60","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1097\/00001756-199705260-00040","article-title":"Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor","volume":"8","author":"Rietschel","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib61","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(96)00090-5","article-title":"Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene","volume":"15","author":"Rietschel","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/j.1875-9114.1996.tb02930.x","article-title":"Pathophysiology of schizophrenia and the role of newer antipsychotics","volume":"16","author":"Risch","year":"1996","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib63","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2165\/11596300-000000000-00000","article-title":"Atypical antipsychotic-induced weight gain: insights into mechanisms of action","volume":"25","author":"Roerig","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib64","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.pnpbp.2012.05.007","article-title":"Possible impact of ADRB3 Trp64Arg polymorphism on BMI in patients with schizophrenia","volume":"38","author":"Sasayama","year":"2012","journal-title":"Prog. Neuro -Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib65","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0924-977X(99)00044-9","article-title":"Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients","volume":"10","author":"Scharfetter","year":"1999","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib66","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0140-6736(05)74176-3","article-title":"Pharmacogenetics of the clozapine response","volume":"356","author":"Schumacher","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib67","first-page":"602","article-title":"Dopamine receptor pharmacology","volume":"6","author":"Seeman","year":"1993","journal-title":"Curr. Opin. Neurol. Neurosurg."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib503","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/0140-6736(93)92594-J","article-title":"Dopamine D4 receptor subtypes and response to clozapine","volume":"341","author":"Shaikh","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib504","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ajmg.1320600611","article-title":"Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients","volume":"60","author":"Shaikh","year":"1995","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib505","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/BF02346178","article-title":"Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia","volume":"97","author":"Shaikh","year":"1996","journal-title":"Hum Genet."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib68","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11920-014-0473-9","article-title":"Antipsychotic induced weight gain: genetics, epigenetics, and biomarkers reviewed","volume":"16","author":"Shams","year":"2014","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib69","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2217\/pgs.10.123","article-title":"Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis","volume":"11","author":"Sicard","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib70","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2217\/pgs.09.43","article-title":"Association of the alpha 2A adrenergic receptor -1291C\/G polymorphism and antipsychotic-induced weight gain in European-Americans","volume":"10","author":"Sickert","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib71","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00001756-199512000-00041","article-title":"Association between clozapine response and allelic variation in the 5-HT2C receptor gene","volume":"7","author":"Sodhi","year":"1995","journal-title":"Neuroreport"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib72","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/FPC.0b013e328337ce3e","article-title":"Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia","volume":"20","author":"Souza","year":"2010","journal-title":"Pharmacogenet Genom."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib73","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jpsychires.2010.01.002","article-title":"Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response","volume":"44","author":"Souza","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib74","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00041444-200512000-00011","article-title":"Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs","volume":"15","author":"Theisen","year":"2005","journal-title":"Psychiatr. Genet."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib75","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0920-9964(00)00127-4","article-title":"Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response","volume":"49","author":"Tsai","year":"2001","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib76","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000077939","article-title":"Association study of adrenergic beta3 receptor (Trp64Arg) and G-protein beta3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment","volume":"50","author":"Tsai","year":"2004","journal-title":"Neuropsychobiology"},{"issue":"Suppl B","key":"10.1016\/j.euroneuro.2015.12.035_bib77","first-page":"157","article-title":"Clozapine and weight gain","volume":"55","author":"Umbricht","year":"1994","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib78","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0014-2999(00)00814-1","article-title":"Pharmacogenetics and the serotonin system: initial studies and future directions","volume":"410","author":"Veenstra-VanderWeele","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib79","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(96)91594-9","article-title":"Monozygotic twins concordant for response to clozapine","volume":"347","author":"Vojvoda","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib80","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/01.fpc.0000175600.26893.fa","article-title":"C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population","volume":"15","author":"Wang","year":"2005","journal-title":"Pharmacogenet Genom."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib81","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00702-005-0291-7","article-title":"Polymorphism of the adrenergic receptor alpha 2a -1291C>G genetic variation and clozapine-induced weight gain","volume":"112","author":"Wang","year":"2005","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib82","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/hup.1122","article-title":"Genetic association between TNF-alpha -308 G>A polymorphism and longitudinal weight change during clozapine treatment","volume":"25","author":"Wang","year":"2010","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib83","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.psychres.2004.02.018","article-title":"Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation","volume":"133","author":"Wehmeier","year":"2005","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib84","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/cn400121z","article-title":"Classics in chemical neuroscience: clozapine","volume":"4","author":"Wenthur","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib85","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.schres.2006.10.002","article-title":"COMT val108\/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia","volume":"90","author":"Woodward","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib86","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1097\/00001756-199904260-00014","article-title":"Serotonin-6 receptor variant (C267T) and clinical response to clozapine","volume":"10","author":"Yu","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib87","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000054871","article-title":"Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T\/C) and increment of N100 amplitude in schizophrenics treated with clozapine","volume":"43","author":"Yu","year":"2001","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib88","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00213-006-0482-4","article-title":"Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication","volume":"188","author":"Zai","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.12.035_bib89","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1517\/17425255.2011.532787","article-title":"Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction","volume":"7","author":"Zhang","year":"2011","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib90","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1517\/17425255.2013.736964","article-title":"Pharmacogenetics of antipsychotics: recent progress and methodological issues","volume":"9","author":"Zhang","year":"2013","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"key":"10.1016\/j.euroneuro.2015.12.035_bib91","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/00207450590957863","article-title":"Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine","volume":"115","author":"Zhao","year":"2005","journal-title":"Int. J. Neurosci."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X15004186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X15004186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T12:39:17Z","timestamp":1718282357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X15004186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0924977X15004186"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.12.035","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetics of clozapine response and induced weight gain: A comprehensive review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.12.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}